Allarity Therapeutics Inc (ALLR) Stock Price, Quote & News

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology

Sector: Healthcare

Phone: 401 426 4664

Website: www.allarity.com

Address:

123 E. Tarpon Ave., Tarpon Springs, United States

Dizzier47 Aug. 19 at 11:13 AM

$ALLR

0 · Reply

Kvakklunch Aug. 18 at 7:20 PM

$ALLR Downtrend is now confirmed. Will go down 2-5% everyday.

0 · Reply

Kvakklunch Aug. 18 at 3:35 PM

$ALLR Dilution is imminent! Sell your stocks and save your money!

0 · Reply

MichaelSctock Aug. 18 at 2:57 PM

$ALLR hmm..that 1.25 retest is intriguing. Let’s see 🤔

0 · Reply

Kvakklunch Aug. 18 at 2:19 PM

$ALLR Dumping hard!

0 · Reply

Kvakklunch Aug. 18 at 11:19 AM

$ALLR I think we will see 1.20's today.

0 · Reply

Dizzier47 Aug. 18 at 10:28 AM

$ALLR stenoparib is the greatest thing of the year 2026 > eisai want to buy it back > other big pharma enter a bidding war > finally buyout for 15bil aka 1k$~ per share and everyone here retires a millionaire.

1 · Reply

Dizzier47 Aug. 18 at 9:24 AM

$ALLR red is the colour of the danish flag

0 · Reply

Kvakklunch Aug. 17 at 9:17 PM

$ALLR Red is the color for this company!

0 · Reply

Kvakklunch Aug. 17 at 8:52 PM

$ALLR

0 · Reply

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Jul 7, 2026, 8:00 AM EDT - 6 weeks ago

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Jun 30, 2026, 8:00 AM EDT - 7 weeks ago

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

2026-06-18T12:18:06.000Z - 2 months ago

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

Jun 18, 2026, 8:00 AM EDT - 2 months ago

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

May 15, 2026, 4:30 PM EDT - 3 months ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

May 8, 2026, 8:45 AM EDT - 3 months ago

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 5, 2026, 8:00 AM EDT - 3 months ago

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

2026-04-27T13:21:02.000Z - 4 months ago

Allarity receives notice of allowance from USPTO

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

2026-03-06T13:19:41.000Z - 5 months ago

Allarity closes $20M financing for stenoparib advancement

Mar 6, 2026, 8:00 AM EST - 5 months ago

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

2026-02-18T13:25:56.000Z - 6 months ago

Allarity doses first patients in Phase 2 trial of SCLC

Feb 18, 2026, 8:15 AM EST - 6 months ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

2026-02-03T13:20:33.000Z - 7 months ago

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

Feb 3, 2026, 8:00 AM EST - 7 months ago

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

2025-12-31T13:05:34.000Z - 8 months ago

Allarity CEO says 2026 represents an ‘inflection point’

Dec 31, 2025, 8:00 AM EST - 8 months ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

2025-12-03T14:15:27.000Z - 9 months ago

Allarity files $50M mixed securities shelf

2025-11-14T14:06:08.000Z - 9 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year

Nov 14, 2025, 9:00 AM EST - 9 months ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

2025-09-25T21:25:29.000Z - 11 months ago

Allarity files to sell 1.56M shares of common stock for holders

2025-09-22T12:20:54.000Z - 11 months ago

Allarity presents new Phase 2 clinical data for Stenoparib

Sep 22, 2025, 8:00 AM EDT - 11 months ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

2025-08-27T01:00:00.000Z - 1 year ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-26T12:05:59.000Z - 1 year ago

Allarity announces FDA granted Fast Track designation to stenoparib

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 15, 2025, 4:30 PM EDT - 1 year ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

2025-07-28T09:50:42.000Z - 1 year ago

Allarity initiated with a Buy at Ascendiant

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

2025-07-07T12:26:02.000Z - 1 year ago

Allarity appoints Jeff Ervin as CFO

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

2025-06-30T14:34:35.000Z - 1 year ago

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

2025-06-27T12:10:38.000Z - 1 year ago

Allarity announces second patient dosed in Phase 2 trial of stenoparib

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 11, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Announces Changes to Board of Directors

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI

2025-06-02T12:30:27.000Z - 1 year ago

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

May 9, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Feb 24, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Jan 30, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Nov 18, 2024, 8:00 AM EST - 1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Dizzier47 Aug. 19 at 11:13 AM

$ALLR

0 · Reply

Kvakklunch Aug. 18 at 7:20 PM

$ALLR Downtrend is now confirmed. Will go down 2-5% everyday.

0 · Reply

Kvakklunch Aug. 18 at 3:35 PM

$ALLR Dilution is imminent! Sell your stocks and save your money!

0 · Reply

MichaelSctock Aug. 18 at 2:57 PM

$ALLR hmm..that 1.25 retest is intriguing. Let’s see 🤔

0 · Reply

Kvakklunch Aug. 18 at 2:19 PM

$ALLR Dumping hard!

0 · Reply

Kvakklunch Aug. 18 at 11:19 AM

$ALLR I think we will see 1.20's today.

0 · Reply

Dizzier47 Aug. 18 at 10:28 AM

1 · Reply

Dizzier47 Aug. 18 at 9:24 AM

$ALLR red is the colour of the danish flag

0 · Reply

Kvakklunch Aug. 17 at 9:17 PM

$ALLR Red is the color for this company!

0 · Reply

Kvakklunch Aug. 17 at 8:52 PM

$ALLR

0 · Reply

JimmyOcarri Aug. 17 at 8:42 PM

$ALLR $CODX $CABR $SNOA $HUIZ game

1 · Reply

TupacLive Aug. 17 at 8:35 PM

$ALLR

0 · Reply

Wody Aug. 17 at 8:34 PM

$ALLR now we bleed until news? C’mon

0 · Reply

Kvakklunch Aug. 17 at 7:17 PM

$ALLR Slowly declining on a lower top than the previous one. Yep, we all know this story....

0 · Reply

Dizzier47 Aug. 17 at 5:24 PM

$ALLR 110$ and I'm getting a tattoo of a Danish hero

1 · Reply

Wody Aug. 17 at 3:06 PM

$ALLR

0 · Reply

Kvakklunch Aug. 17 at 2:47 PM

$ALLR No news for two months. Come on...

0 · Reply

ZacksResearch Aug. 17 at 1:33 PM

📊 $ALLR beats Q2 EPS estimates as stenoparib moves closer to pivotal development Allarity reported a narrower-than-expected Q2 loss while making further progress with its lead cancer candidate, stenoparib. Key takeaways: • EPS: Loss of $0.21/share, beating the $0.25 Zacks Consensus Estimate • Q2 net loss narrowed to $3.4M from $4.2M in the year-ago quarter • Allarity completed its Phase 3-ready stenoparib manufacturing campaign • A key U.S. patent protects stenoparib use with its DRP® companion diagnostic into 2042 • The company ended Q2 with $26.9M in cash and restricted cash Price target breakdown here 👇 https://www.zacks.com/stock/research/ALLR/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-39270&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_39270

0 · Reply

Dizzier47 Aug. 16 at 4:25 PM

$ALLR 100$ eoy and im changing my name to thomas

1 · Reply

RAKIN13 Aug. 13 at 8:37 PM

$ALLR bored af

0 · Reply

Wody Aug. 13 at 7:49 PM

$ALLR some shady shit going on…

1 · Reply

Dizzier47 Aug. 13 at 6:07 PM

$ALLR negative volume day big things coming

0 · Reply

Market Cap	21.32M
Revenue (ttm)	320,000.00
Net Income (ttm)	-11.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,509.37%
Debt to Equity Ratio	0.21

Volume	52,500
Avg Vol	113,036
Day's Range	N/A - N/A
Shares Out	15.91M
Stochastic %K	33%
Beta	0.51
Analysts	Sell
Price Target	$10.25